Ebglyss Dosage

Vaccination Prior to Administration of EBGLYSS

Complete all age-appropriate vaccinations according to current immunization guidelines.

Recommended Dosage

The recommended dosage of EBGLYSS is an initial dose of 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dosage is 250 mg every four weeks.

Concomitant Topical Therapies

EBGLYSS can be used with or without topical corticosteroids (TCS). Topical calcineurin inhibitors (TCI) may be used, but reserved for sensitive areas only, such as the face, neck, intertriginous and genital areas.

Important Administration Instructions

• EBGLYSS is for subcutaneous administration.
• EBGLYSS is intended for use under the guidance of a healthcare professional. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of EBGLYSS. Adult patients may self-inject, or caregivers may give EBGLYSS after training in subcutaneous injection technique. For pediatric patients, caregivers may give injections after training in subcutaneous injection technique.
• Sites for injection include the abdomen, thigh, and back of the upper arm. Administration of EBGLYSS in the back of the upper arm may be performed by a caregiver or healthcare provider.
• Alternate the injection site with each injection. Do not inject EBGLYSS within 2 inches (5 cm) of the navel or into areas where the skin is tender, bruised, red, hard, or in an area of skin that is affected by atopic dermatitis or skin lesions.
• Before injection, remove EBGLYSS prefilled pen or EBGLYSS prefilled syringe from the refrigerator. If using:
  • EBGLYSS prefilled pen, it is not necessary to warm up to room temperature before use.
  • EBGLYSS prefilled syringe, leave at room temperature for 45 minutes without removing the needle cap. Do not warm EBGLYSS by using a heat source such as hot water, microwave, or direct sunlight. Protect EBGLYSS from light until use.
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. EBGLYSS is a clear to opalescent, colorless to slightly yellow to slightly brown solution. Do not use if the liquid contains visible particles, is discolored or cloudy.
• Refer to the Instructions for Use for complete administration instructions with illustrations.

Missed Dose

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.